Rigel
corporate overview

pipeline

investors & media

careers




Lupus Overview Presentation


A novel Syk inhibitor for SLE:
  • Systemic lupus erythematosus (SLE), or lupus, is an autoimmune disease characterized by excessive and chronic activation of inflammatory pathways.

  • The Lupus Foundation of America (LFA) estimates between 1.5 - 2 million Americans have a form of lupus. More than 90 percent of people with lupus are women.

  • The disease affects various parts of the body including the skin, joints, kidneys, heart, lungs and brain. If left untreated, the SLE may ultimately destory the involved organ.

Highlights:
  • Preclinical studies have shown that R788 is highly effective in a murine model of lupus.


Latest News:

Disease background
SLE is an autoimmune disease that affects various parts of the body including the kidneys, skin, joints, heart, lungs and brain. Its effects can be mild, limited to a couple of organs in the body and occasional flare-ups, or can cause serious and life-threatening complications. Like other autoimmune diseases the primary characteristic of lupus is inflammation which causes swelling, pain, loss of function and may ultimately destroy the involved organ if left untreated.

Current therapies for lupus treat the symptoms of the disease and include non steroidal anti-inflammatory drugs (NSAIDS), corticosteroids, anti-malarial agents and, in severe cases where organ damage is at risk, immunosuppressant drugs.

© 2008 Rigel  |  privacy  |  disclaimer contact us  |  site map  |  search    Search